home / stock / atnfw / atnfw quote
Last: | $0.01 |
---|---|
Change Percent: | 5.56% |
Open: | $0.0085 |
Close: | $0.01 |
High: | $0.010199 |
Low: | $0.0085 |
Volume: | 9,825 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.01 | $0.0085 | $0.01 | $0.010199 | $0.0085 | 9,825 | 04-26-2024 |
$0.009 | $0.0085 | $0.009 | $0.0099 | $0.0085 | 3,370 | 04-25-2024 |
$0.0083 | $0.01 | $0.0083 | $0.01 | $0.0083 | 1,172 | 04-24-2024 |
$0.0099 | $0.01 | $0.0099 | $0.01 | $0.0081 | 11,741 | 04-23-2024 |
$0.0093 | $0.0093 | $0.0093 | $0.009401 | $0.0087 | 32,214 | 04-22-2024 |
$0.0099 | $0 | $0.0099 | $0 | $0 | 129 | 04-19-2024 |
$0.0099 | $0.01 | $0.0099 | $0.01 | $0.0071 | 12,774 | 04-18-2024 |
$0.01 | $0.00904 | $0.01 | $0.01 | $0.00904 | 31,663 | 04-17-2024 |
$0.01 | $0.0082 | $0.01 | $0.01 | $0.0073 | 70,407 | 04-16-2024 |
$0.0082 | $0.01 | $0.0082 | $0.0116 | $0.0082 | 11,446 | 04-15-2024 |
$0.0088 | $0.014 | $0.0088 | $0.014 | $0.0082 | 46,937 | 04-12-2024 |
$0.0099 | $0.01 | $0.0099 | $0.0105 | $0.008 | 21,113 | 04-10-2024 |
$0.009 | $0.009 | $0.009 | $0.0091 | $0.009 | 13,263 | 04-09-2024 |
$0.0084 | $0.0076 | $0.0084 | $0.009101 | $0.0075 | 37,162 | 04-08-2024 |
$0.0082 | $0.0082 | $0.0082 | $0.0096 | $0.0082 | 54,986 | 04-05-2024 |
$0.0089 | $0.0071 | $0.0089 | $0.0089 | $0.0071 | 1,018 | 04-04-2024 |
$0.008 | $0.0082 | $0.008 | $0.01 | $0.0079 | 52,256 | 04-03-2024 |
$0.012 | $0.0068 | $0.012 | $0.0123 | $0.0068 | 29,089 | 04-02-2024 |
$0.0082 | $0.0082 | $0.0082 | $0.0082 | $0.0082 | 1,106 | 04-01-2024 |
$0.0082 | $0.0125 | $0.0082 | $0.0125 | $0.0067 | 30,102 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 Company Name:
ATNFW Stock Symbol:
NASDAQ Market:
MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
MENLO PARK, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
MENLO PARK, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in i...